Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hepatocellular carcinoma (HCC) with cardiac metastasis represents a group of rarity and poor prognosis. Few case reports have described this patient entity, and it remains unclear regarding the optimal treatment and predicted outcome for these patients. In our case, we represented a 67-year-old female patient with presentations of dyspnea and heart murmur, which conducted to the diagnosis of advanced HCC with isolated right ventricular metastasis. Because of multiple comorbidities regarding cardiac and pulmonary systems, she received best supportive care and survived 2 months after initial diagnosis. A systemic literature review of 80 published cases (including our patient) since the 1950s was also performed from PubMed, and the data were gathered from the medical record and literature reviews. In our review, patients with advanced HCC and cardiac metastasis involved the right heart mainly with a predominance of right atrium (53%). Meanwhile the overall 3-month survival rate in our review was 70.7%. In subgroup analysis, the overall 3-month survival was highest (97%) in patients treated with surgery and other therapies, and lowest (27%) in patients with best supportive care. To our knowledge, this is the first comprehensive literature review addressing the epidemiology, optimal treatment, and prognosis for advanced-stage HCC with cardiac metastasis. We suggest that abnormal cardiac murmur in patients with history of HCC should prompt investigation for tumor involvement of the heart. We also emphasize individualized treatment as well as prognostic measurement accordingly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940437 | PMC |
| http://dx.doi.org/10.1159/000504566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in hepatocellular carcinoma cells.
J Ethnopharmacol
September 2025
School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, 418000, Hunan, China. Electronic address:
Objective: This study aimed to integrate network pharmacology, bioinformatics analysis, molecular docking, and experimental validation to construct a "component-target-pathway" multidimensional network model, systematically elucidate the potential mechanisms underlying the therapeutic effects of the extract of Potentilla freyniana Bornm. (PFB) on hepatocellular carcinoma (HCC), and thereby clarify its pharmacological basis.
Methods: HCC datasets were retrieved from GEO and TCGA databases, and the DEGs were screened.
Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea.
J Liver Cancer
September 2025
The Korean Liver Cancer Association, Seoul, Korea.
In 2024, a nationwide conflict between the South Korean government and the medical community, the medical-policy conflict, profoundly impacted healthcare delivery. This study aimed to evaluate the changes in the management of hepatocellular carcinoma (HCC) following this crisis. We analyzed retrospective real-world data from university hospitals in the Seoul metropolitan area, supplemented with national healthcare data from the Health Insurance Review and Assessment Service.
View Article and Find Full Text PDFAssociation between inflammatory biomarkers, chronic stress, and pericoronary adipose tissue attenuation obtained with coronary CT.
Eur Heart J Cardiovasc Imaging
August 2025
Cardiac Imaging, Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.
Aims: Pericoronary adipose tissue (PCAT) attenuation is a novel imaging biomarker of coronary inflammation associated with an increased risk of coronary artery disease (CAD). However, no studies have examined the relationship between chronic stress and PCAT. This study aimed to evaluate the intersection between chronic stress, inflammatory biomarkers, coronary plaque features, and PCAT attenuation.
View Article and Find Full Text PDFDual-Targeting Peptide Assembly Probe for Precise Detection of Biomarkers of Circulating Tumor Cells in Hepatocellular Carcinoma.
Small
August 2025
Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Med
Hepatocellular carcinoma (HCC) represents the predominant malignant hepatic neoplasm globally and constitutes a principal contributor to cancer-associated mortality. Contemporary diagnostic methodologies exhibit limited sensitivity for early-stage detection, while the disease's substantial metastatic propensity and recurrence rates significantly compromise survival outcomes. Circulating tumor cells (CTCs), detectable throughout disease progression and harboring crucial pathological signatures, present compelling potential as liquid biopsy biomarkers for early-stage detection and prognostic assessment.
View Article and Find Full Text PDFtoxicity assessment of cysteamine-modified nanoparticles: implications for pharmacotherapy application.
Toxicol Mech Methods
September 2025
Department of Pharmacology and Therapeutics, Delta State University, Abraka, Delta State, Nigeria.
Background: Given the increasing therapeutic potential of cysteamine (CYST) at appropriate doses and expert concerns regarding the toxicity of nanoparticles, this study aimed to assess the toxicity profile of both CYST and silver nanoparticles conjugated with cysteamine (CYST-AgNPs).
Methods: For the acute study, a 300 mg/kg starting dose of CYST (i.p administration) produced a toxic response in some mice ( = 3/group), and a 300 mg/kg beginning dose of CYST-AgNPs produced delayed mild toxicity.